Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 / prevention & control
  • COVID-19 Vaccines*
  • Humans
  • Infliximab*
  • Janus Kinase Inhibitors*
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • Infliximab
  • tofacitinib
  • Janus Kinase Inhibitors

Supplementary concepts

  • SARS-CoV-2 variants